As per a recent market survey by ESOMAR-certified consulting firm Future Market Insights (FMI), Liquid Biopsy Market Size is expected to reach a market valuation of US$ 1,026 Mn in 2021.

With the introduction of innovative molecular diagnostic tests and growing demand from biotech and pharmaceutical companies, the market is poised to expand at a stellar 13.49% CAGR, reaching US$ 3,637 Mn by 2031.

Growth of the liquid biopsy market is attributable to rising incidence of cancer across several countries, which is highlighting the pressing need for faster, simpler, and more convenient diagnostic procedures. Liquid biopsy procedures are minimally invasive and cost-effective, which is making them a favorable choice for cancer diagnosis procedures.

Besides this, increasing government-backed initiatives to support cancer research across the U.S., Japan, India and the UK will drive innovation and developments in liquid biopsy services. Also, fast track approval from regulatory bodies for novel procedures will bolster the growth over the coming years.

Major Players:

BIOCEPT, INC., Qiagen N.V., Trovagene, Inc, Janssen Global Services, LLC, MDxHealth SA, Natera, Inc, F. Hoffmann-La Roche Ltd, Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation are among top manufacturers of liquid biopsy products, as profiled by FMI. As per the market survey, tier-1 companies are anticipated to account for approximately 20-25% of the total market share.

Key Takeaways from the Liquid Biopsy Market Analysis

Based on markers, circular tumor cells (CTC) are poised to emerge dominant in the forthcoming years.
Blood samples will emerge as the most preferred sample type
The U.S. will showcase high growth during the forecast period, due to the presence of major liquid biopsy product manufacturers.
The U.K. will emerge as an avenue for product innovations and development, further solidifying growth prospects.
Japan is anticipated to witness upswings in sales, owing to government-led cancer research initiatives.
India is expected to showcase high demand for liquid biopsy products, owing to the increased funding by government and expansion of healthcare infrastructure.
Germany, India, and China will emerge as high growth potential markets, with increasing investments by the government for improving the healthcare infrastructure, which will create attractive opportunities to global biotech players for market expansion.
Why Future Market Insights?

Comprehensive analysis on evolving purchase pattern across different geographies

Detailed insights of market segments and sub-segments for historical as well as forecast period

A competitive analysis of prominent players and emerging players in the keyword market

Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Information Source: https://www.futuremarketinsights.com/reports/liquid-biopsy-market